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Abstract To investigate the role of heparin-binding EGF-like
growth factor (HB-EGF) in skeletal muscle, we studied its
function in skeletal myotubes in vitro using mouse C2C12 cells.
Expression levels of membrane-anchored HB-EGF (proHB-
EGF) protein were increased specifically during their differentia-
tion among epidermal growth factor receptor (EGFR) ligands.
Production levels of EGFR on the cell surface were constant.
Tyrosine phosphorylation of EGFR, however, was constitutively
increased during differentiation. Quenching of endogenous HB-
EGF significantly rendered myotubes sensitive to apoptotic cell
death induced by hypoxic stress, suggesting that proHB-EGF in
the skeletal muscle is specifically upregulated to function as a
survival factor.
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1. Introduction
Skeletal muscle cells provide a typical example of terminal
di¡erentiation [1]. Their proliferating precursor cells, myo-
blasts, express at least one muscle regulatory gene of the
MyoD family [2] and can be introduced into the muscle di¡er-
entiation lineage by the withdrawal of growth factors in vitro.
Growth factor-starved myoblasts irreversibly exit from the cell
cycle, becoming terminally di¡erentiated myotubes which are
multinucleated fused cells [1], and do not proliferate further.
However, they simultaneously produce both growth factors
and their receptors, indicating that some autocrine mechanism
may exist. Heparin-binding EGF-like growth factor (HB-
EGF) transcript is highly expressed in skeletal muscle [3]
and is driven by MyoD [4]. Since epidermal growth factor
receptor (EGFR), which binds to HB-EGF, is expressed in
myotubes, possible interactions of HB-EGF and EGFR and
their physiological function may play a critical role in the
formation or the functional maintenance of terminally di¡er-
entiated myotubes.
HB-EGF was originally identi¢ed as a mitogenic protein
with 76^87 amino acid residues for vascular smooth muscle
cells [5,6]. HB-EGF, like other members of the EGF family, is
initially synthesized as a membrane-anchored form (proHB-
EGF) that can be processed to release the soluble form (sHB-
EGF). ProHB-EGF tethered to the cell surface also stimulates
adjacent cell growth through cell-cell contact, termed a juxta-
crine manner [7]. In addition to the growth factor activity,
proHB-EGF also functions as a diphtheria toxin receptor
[8,9] and exists in muscle cells [3]. These data are consistent
with the fact that the skeletal and cardiac muscles are the
most sensitive organs to diphtheria toxin [10]. The present
study reports an investigation of the physiological role of
HB-EGF, particularly its membrane-anchored form in the
skeletal muscle cells.
2. Materials and methods
2.1. Materials
Sulfo-NHS-biotin was purchased from Pierce (Rockford, IL, USA).
An enhanced chemiluminescence (ECL) kit was purchased from
Amersham (Buckinghamshire, UK). Human HB-EGF neutralizing
antibodies #197 and #H1 were described previously [11,12]. Tyrphos-
tin AG1478 was purchased from Calbiochem (La Jolla, CA, USA).
Phosphotyrosine antibody PY-20 was from Transduction Laboratory
(Lexington, KY, USA). An antisense phosphorothiolate oligonucleo-
tide, complementary to the 1^27 nucleotide sequence of the open
reading frame of HB-EGF cDNA, and the corresponding sense phos-
phorothiolate oligonucleotide were prepared by Griner Japan (Tokyo,
Japan). [125I]EGF was purchased from ICN (Costa Mesa, CA, USA).
2.2. Cell culture
A mouse muscle myoblast C2C12 cell line was obtained from
ATCC and maintained in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 20% fetal calf serum (FCS) and, unless
otherwise indicated, the cell culture media contained penicillin (100 U/
ml) and streptomycin (100 Wg/ml). In order to di¡erentiate C2C12
myoblasts into myotubes, the medium was changed to a di¡erentia-
tion medium (DMEM supplemented with 2% horse serum).
2.3. Biotinylation and immunoprecipitation of proHB-EGF
In order to detect proHB-EGF, cell surface biotinylation, immuno-
precipitation and Western blotting were carried out as described pre-
viously [13].
2.4. Growth factor assay
To measure the mitogenic activity of HB-EGF, an EP170.7 cell
assay was carried out as described previously [7].
2.5. Detection of tyrosine-phosphorylated EGF receptor
Tyrosine-phosphorylated EGF receptor was identi¢ed using phos-
photyrosine antibody PY-20. Subcon£uent undi¡erentiated and di¡er-
entiated C2C12 cells in 10 cm dishes were lysed with a lysis bu¡er and
immunoprecipitated with PY-20 as described previously [6]. Precipi-
tated proteins were separated by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE), transferred electrically to a
nitrocellulose membrane and probed with PY-20, followed by horse-
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radish peroxidase (HRP)-conjugated goat anti-mouse IgG (Amer-
sham). The membranes were then treated with detection reagents
for ECL Western blotting for 1 min (Amersham) at room temper-
ature.
2.6. Northern blot analyses
Total RNA from cultured C2C12 cells was prepared by the acid
guanidinium thiocyanate/phenol/chloroform method [14]. Eighteen Wg
of total RNA/lane was fractionated on a 1.0% formaldehyde-agarose
gel and transferred onto a Zeta probe (Bio-Rad) membrane by capil-
lary action as described previously [15].
2.7. Released lactate dehydrogenase (LDH) measurements
Released LDH was measured using a MTX‘LDH’ kit (Kyokuto
Pharmaceutical Industrial, Tokyo, Japan). C2C12 myotubes, cultured
in a 96-well plate, were incubated for 16 h under hypoxic conditions
using an AnaeroPack (Mitsubishi Gas Chemical, Tokyo, Japan).
Twenty-¢ve Wl of each cultured medium was transferred to another
96-well plate. Twenty-¢ve Wl of coloring solution (0.74 mg/ml 2-p-
iodophenyl-3-p-nitrophenyl tetrazolium chloride, 50 mg/ml lithium
lactate) was then added to each well. The plates were incubated at
37‡C for 5 min and the reaction was stopped by addition of 50 Wl of
1 M HCl and the absorbance at 560 nm was measured. The amount
of released LDH was calculated according to the following formula:
% absorbance = ((T3PC)/(NC3PC))U100 (T, absorbance of total
LDH from cells; PC, absorbance of the released LDH from cells
cultured under normal conditions; NC, absorbance of the released
LDH from cells cultured for 24 h under hypoxic conditions).
2.8. [125I]EGF binding
[125I]EGF binding was carried out according to the method de-
scribed previously [5,6]. Brie£y, the C2C12 cells, plated in 24-well
plates, were washed twice with ice-cold phosphate-bu¡ered saline
(PBS) containing 1 mg/ml bovine serum albumin (BSA-PBS). Increas-
ing amounts of [125I]EGF (3.93U108 cpm/Wg) were added and the
cells were incubated for 1 h at 4‡C. The cells were washed three times
with ice-cold BSA-PBS and lysed with 0.2 N NaOH. Cell-associated
radioactivity was measured on a Q-counter (Beckman). Non-speci¢c
binding of [125I]EGF was assessed in the presence of a 60-fold excess
of cold EGF. Speci¢c binding was determined by subtracting the non-
speci¢c binding. The non-speci¢c binding was less than 10% of the
total binding.
2.9. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted from the C2C12 cell line as described
above. Five Wg of total RNA was used for cDNA synthesis in a
reaction mixture containing 75 mM KCl, 50 mM Tris-HCl, pH 8.3,
3 mM MgCl2, 10 mM DTT, 0.5 Wg of oligo(dT) primer (Gibco BRL,
Gaithersburg, MD, USA), 0.25 mM dNTPs, 6 U of Rous-associated
virus 2 reverse transcriptase (Takara, Osaka, Japan). After incubation
for 60 min at 37‡C, the cDNA obtained was subjected to 35 cycles of
PCR [16] (94‡C, 1 min; 55‡C, 2 min; 72‡C, 3 min) using the following
speci¢c primers for EGF: 5P-CACTGAGCAACTCCACTCAG-3P
and 5P-CACATCCCCAAGAGGAGCAG-3P, TGF-K : 5P-ATGGTC-
CCCGCGACCGGACA-3P and 5P-TTCAGACCACTGTCTCAGA-
G-3P, betacellulin: 5P-GGTCTTGCAATTCTCCACTG-3P and 5P-G-
CTTGTGATAACTTTATAAC-3P, amphiregulin: 5P-GGTGGAAC-
CAATGAGAACTC-3P and 5P-CATCCGAAAGCTCCACTTCC-3P,
epiregulin: 5P-CGCAAGCTGCACCGAGAAAG-3P and 5P-CTTGT-
CCGTAACTTGATGGC-3P and the PCR products were ampli¢ed.
The PCR products were electrophoresed on a 1.2% agarose gel and
stained with ethidium bromide prior to visualization using ultraviolet
light.
2.10. Detection of apoptotic cell death
Apoptotically dead cells were detected using an in situ detection kit
(Takara) according to the manufacturer’s protocol. Di¡erentiated
C2C12 cells were cultured in a two well chamber slide and incubated
for 8 h under hypoxic conditions. Cells were ¢xed with freshly pre-
pared 4% paraformaldehyde in PBS, pH 7.4, for 30 min at room
temperature, and washed three times with PBS. The ¢xed cells were
incubated with a permeation bu¡er for 5 min on ice and washed three
times with PBS. The cells were then incubated with a labelling bu¡er
for 90 min, washed with PBS and viewed on an inverted £uorescence
microscope.
3. Results
3.1. HB-EGF mRNA and protein expression levels in C2C12
cells
To analyze the physiological roles of HB-EGF in the my-
otube, we examined HB-EGF expression in pre- and post-
di¡erentiated mouse myoblast C2C12 cells in vitro. Northern
blot analyses were carried out to examine the expression level
of HB-EGF mRNA in C2C12 cells. A 2.5 kb transcript of
HB-EGF was detected in both pre- and post-di¡erentiated
C2C12 cells and the HB-EGF mRNA expression level was
Fig. 1. Expression of HB-EGF and EGFR in C2C12 cells. (A)
Northern blotting analyses of HB-EGF mRNA. Total RNA (18
Wg), prepared from undi¡erentiated and di¡erentiated C2C12 cells,
was electrophoresed in a 1% agarose, immobilized to Hybond N
(Amersham) and hybridized with a 32P-labelled HB-EGF cDNA
probe. (B) Immunoprecipitation of biotinylated proHB-EGF. Undif-
ferentiated and di¡erentiated C2C12 cells were biotinylated and im-
munoprecipitated by HB-EGF antibody #H1. The precipitated
proHB-EGF was then subjected to SDS-PAGE, Western blotting
and avidin-HRP detection. ProHB-EGF protein is detected as heter-
ogeneous bands of 14^29 kDa [13]. (C) Western blot analysis of
proteins with phosphorylated tyrosines. Di¡erentiated and undi¡er-
entiated C2C12 cells were lysed with 1% Triton X-100 solution and
immunoprecipitated with phosphotyrosine antibody PY-20. The pre-
cipitated proteins were subjected to SDS-PAGE, followed by West-
ern blotting with PY-20. Di¡erentiated C2C12 cells treated with
HB-EGF neutralizing antibody #197 or normal goat IgG at a ¢nal
concentration of 100 ng/ml were also subjected to immunoprecipita-
tion and Western blotting by phosphotyrosine antibody PY-20. (D)
[125I]EGF binding to di¡erentiated and undi¡erentiated C2C12 cells.
[125I]EGF speci¢c binding was estimated in the presence or absence
of a 60-fold excess of cold EGF.
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elevated by approximately two-fold during di¡erentiation
(Fig. 1A). To investigate the upregulation of the protein pro-
duction during the di¡erentiation, qualitative analyses were
carried out to estimate processed HB-EGF (sHB-EGF) and
proHB-EGF. sHB-EGF activities in the conditioned media of
48 h cultured pre- and post-di¡erentiated C2C12 cells were
not detected by the growth factor assay using EP170.7 cells
(data not shown). The proHB-EGF protein was detected by
combination analyses of cell surface biotinylation and immu-
noprecipitation and was identi¢ed as heterogeneous bands of
14^29 kDa as reported previously (Fig. 1B) [13]. The level of
HB-EGF production, mainly proHB-EGF, was upregulated
more than ¢ve-fold during di¡erentiation. We further exam-
ined whether upregulated proHB-EGF is capable of activating
Fig. 2. E¡ect of anti-tyrosine phosphorylation of EGFR reagent tyr-
phostin AG1478 on C2C12 cell di¡erentiations. (A) Blocking of
EGFR tyrosine phosphorylation by tyrphostin AG1478. Undi¡eren-
tiated C2C12 cells were pre-incubated for 8 h with and without
3 WM tyrphostin. Cells were lysed and immunoprecipitated with
phosphotyrosine antibody PY-20. The precipitates were then sub-
jected to a 6% SDS-PAGE, followed by Western blotting with PY-
20. (B) Phase-contrast photographs of di¡erentiated C2C12 cells in
the presence and absence of tyrphostin AG1478. Subcon£uent
C2C12 cells were cultured in DMEM supplemented with 20% FCS
and 10 nM tyrphostin AG1478 for 12 h. Cells were exposed to dif-
ferentiation medium containing 10 nM tyrphostin AG1478 for
4 days.
C
Fig. 3. E¡ects of anti-HB-EGF reagents on di¡erentiated C2C12
cells under hypoxic conditions. (A) Neutralization of mouse HB-
EGF by anti-human HB-EGF neutralizing antibody #197. Approxi-
mately 10 ng of mouse (closed circle) and human HB-EGFs (open
circle) were pre-incubated with increasing amounts of anti-human
HB-EGF neutralizing antibody #197 and tested for an EP170.7 cell
assay. (B) Blocking of HB-EGF production by antisense oligonu-
cleotide. Di¡erentiated C2C12 cells treated with 10 WM of antisense
or sense oligonucleotide were biotinylated and immunoprecipitated
by HB-EGF antibody #H1. (C) Measurements of released LDH
from di¡erentiated C2C12 cells treated with and without anti-HB-
EGF reagents. Di¡erentiated C2C12 cells were cultured for 8 h in
the presence of 10 Wg/ml HB-EGF neutralizing antibody #197 or 10
WM HB-EGF antisense oligonucleotide under hypoxic conditions us-
ing AnaeroPack. (D) Phase-contrast photographs of di¡erentiated
C2C12 cells treated with oligonucleotides. Myotube disruption in-
duced by hypoxia in the presence of antisense oligonucleotide (left),
but not the sense oligonucleotide (center) of HB-EGF. Di¡erenti-
ated C2C12 cells were cultured for 16 h in the presence of HB-EGF
antisense or sense oligonucleotide. After transferring cells from hy-
poxic to normal, cells were further cultured under normal conditions
for 24 h. Representative phase-contrast photographs of cells are
shown. As a control, the same volume (10 Wl/2 ml) of H2O was
added into the culture medium (right). (E) Apoptotic cell death of
di¡erentiated C2C12 cells. Di¡erentiated C2C12 cells treated with
antisense (left) or sense (right) oligonucleotide of HB-EGF were cul-
tured under hypoxic conditions. Cells were ¢xed, permeated and la-
belled with £uorescenced dUTP. Cells were observed by £uorescence
microscopy.
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endogenous EGFR. Since anti-mouse EGFR antibody for
immunoprecipitation is not yet available, immunoprecipita-
tion and Western blotting with phosphotyrosine antibody
PY-20 and speci¢c blocking of EGFR tyrosine kinase activity
by tyrphostin AG1478 were employed to identify tyrosine-
phosphorylated EGFR. A tyrosine-phosphorylated 180 kDa
band was apparent in post-di¡erentiated C2C12 cells, whereas
it was only faint in pre-di¡erentiated C2C12 cells (Fig. 1C).
Human HB-EGF neutralizing antibody #197 moderately
blocked tyrosine phosphorylation of the 180 kDa band (Fig.
1C), suggesting that the upregulated proHB-EGF activated
the EGF receptor tyrosine kinase. Furthermore, [125I]EGF
binding on pre- and post-di¡erentiated C2C12 cells was car-
ried out to estimate the upregulation of EGFR during di¡er-
entiation. [125I]EGF binding on both types of cells was ob-
served in a dose-dependent manner (Fig. 1D), suggesting that
EGFR production was not a¡ected during di¡erentiation.
These results indicate that proHB-EGF production and
EGFR activation are elevated during di¡erentiation of
C2C12 cells.
3.2. EGFR signaling was not involved in di¡erentiation of
C2C12 cells
Since HB-EGF production and activation of EGFR occur
during di¡erentiation of C2C12 cells, involvement of EGFR
signaling in their di¡erentiation was investigated. C2C12 cells
were cultured with di¡erentiation medium in the presence or
absence of 10 nM tyrphostin, which speci¢cally blocks EGFR
autophosphorylation. The addition of tyrphostin e¡ectively
blocked the tyrosine phosphorylation of a 180 kDa band
(Fig. 2A). However, it had no e¡ect on myotube formation
in C2C12 cells, as shown in Fig. 2B. Collectively, these data
suggest that HB-EGF-EGFR signaling in C2C12 cells is not
involved in their di¡erentiation, despite the fact that its signal-
ing pathway is enhanced (Fig. 2).
3.3. Blocking of HB-EGF or EGFR signi¢cantly enhanced
sensitivity to apoptosis induced by hypoxic stress
To investigate the role of proHB-EGF produced by di¡er-
entiated C2C12 cells, HB-EGF blocking reagents, HB-EGF
neutralizing antibody #197 and antisense oligonucleotide
were used. Firstly, HB-EGF neutralizing antibody #197,
raised against human HB-EGF, partially inhibited mouse
HB-EGF activity (approximately 50% inhibition), while it in-
hibited more than 80% of human HB-EGF activity (Fig. 3A).
Secondly, the antisense oligonucleotide reduced the produc-
tion level of proHB-EGF protein by approximately 30%, as
compared to that of sense oligonucleotide-treated cells (Fig.
3B). C2C12 cells were treated with both reagents under nor-
mal and hypoxic conditions. Measurements of the LDH re-
leased from cells revealed that the amount of released LDH
from cells treated with both reagents was considerably in-
creased as compared to that of their control cells under hy-
poxic conditions (Fig. 3C). After transferring cells from hy-
poxic to normal conditions, myotubes were disrupted in the
presence of the antisense oligonucleotide, whereas they were
well maintained in the presence of sense oligonucleotide or
without oligonucleotides (Fig. 3D). In spite of myotube dis-
ruption, undi¡erentiated myocytes showed no di¡erences in
their growth among the three conditions. On the other
hand, myotube disruption was not induced by antisense oli-
gonucleotide treatment under the normal conditions (data not
shown). These HB-EGF blocking experiments facilitated
apoptotic cell death caused by hypoxic stress (Fig. 3E).
Altogether, this suggests that proHB-EGF-EGFR signaling
is involved in the protection of apoptotic cell death of myo-
tubes induced by hypoxic stress.
3.4. Expression of other members of the EGF family in pre- and
post-di¡erentiated C2C12 cells
Thus far, six members, including HB-EGF, have been iden-
ti¢ed as a ligand for EGFR. To investigate whether other
members of the EGF family are capable of playing a role as
an EGFR ligand in pre- and post-di¡erentiated C2C12 cells,
RT-PCR analyses were carried out to detect their mRNAs. As
shown in Fig. 4, transcripts of EGF, TGF-K, betacellulin,
amphiregulin and epiregulin were detected in pre-di¡erenti-
ated C2C12 cells. The mRNA expression of TGF-K and am-
phiregulin was not detected in the post-di¡erentiated C2C12
cells, whereas betacellulin, amphiregulin and epiregulin tran-
scripts were detected. However, none of their transcriptional
levels was elevated during the di¡erentiation of C2C12 cells.
These results suggest that the speci¢c elevation of HB-EGF
mRNA occurs during di¡erentiation of C2C12 cells into my-
otubes.
4. Discussion
Although HB-EGF has also been shown to be abundantly
expressed in adult skeletal muscle tissues [3], the functional
role of the expressed HB-EGF in skeletal muscle tissues has
not yet been elucidated. It has been reported that EGFR
signaling was not involved in myocyte di¡erentiation [17]. It
is well known that di¡erentiated myotubes do not grow any
more. Then, we focused on the role of HB-EGF in the sur-
vival of myotubes.
Treatment of C2C12 cells with di¡erentiation medium up-
regulated HB-EGF mRNA expression and proHB-EGF pro-
tein levels as shown previously [4]. Activation of EGFR that
binds to HB-EGF was also observed, along with the upregu-
lation of HB-EGF unless EGFR was upregulated. Further
analyses revealed that active proHB-EGF was produced and
not e¡ectively processed to sHB-EGF. This suggests that a
juxtacrine mechanism of HB-EGF might be physiologically
important rather than a paracrine one in myotubes. These
Fig. 4. Expression of the EGF family members during di¡erentia-
tion of C2C12 cells. Thirty-¢ve cycles of PCR were carried out us-
ing cDNAs prepared from di¡erentiated and undi¡erentiated C2C12
cells and speci¢c primers for EGF, TGF-K, betacellulin, amphiregu-
lin and epiregulin. PCR products were electrophoresed on a 1.2%
agarose gel and stained with ethidium bromide. An arrowhead
shows appropriate PCR products.
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¢ndings strongly suggest that the proHB-EGF-EGFR signal-
ing may well be involved in some biological events of myo-
tubes. This view is also supported by the facts that none of the
EGFR ligands, except for HB-EGF, was upregulated during
di¡erentiation.
To investigate the possible roles of HB-EGF in myotubes,
we examined whether or not the survival of the di¡erentiated
C2C12 cells was blocked by HB-EGF neutralizing antibody
or antisense oligonucleotide. These experiments would be ex-
pected to function e¡ectively because of the dominant expres-
sion of HB-EGF among EGFR ligands in skeletal myotubes,
although the blocking e⁄ciencies of both treatments were
estimated to be approximately 50^70%. These treatments to
quench HB-EGF, however, apparently enhanced the release
of LDH, as a result of cell death of the di¡erentiated C2C12
cells under hypoxic conditions. The number of surviving my-
otubes was also signi¢cantly di¡erent after treatments with
and without the quenching reagents under hypoxic conditions.
These ¢ndings strongly support the hypothesis that proHB-
EGF expressed on myotube cell surfaces is able to function to
protect cells from some in£uences of environmental changes,
such as hypoxia, often referred to as a survival factor. The
molecular mechanism underlying this phenomenon remains to
be elucidated. The idea that proHB-EGF also functions as a
survival factor of cardiac myotubes might be supported by the
fact that an early and greatly enhanced response of HB-EGF
gene expression was induced by hypertrophic stimuli in neo-
natal and adult rat cardiac myocytes [18]. Recent studies re-
lating to the molecular mechanisms of the cell division cycle
have suggested that the upregulation of cyclin-dependent ki-
nase inhibitors, such as p21CIP1=WAF1, could be involved in the
terminal di¡erentiation states and might play an important
role in maintaining the quiescent state [19]. Furthermore, it
has been shown that proHB-EGF, but not sHB-EGF, can
induce the upregulation of p21CIP1=WAF1, resulting in the ac-
quisition of cell survival potency in hepatoma cells in our
laboratory [15]. Based on these ¢ndings, p21CIP1=WAF1 regula-
tion by HB-EGF in myotubes was examined after treatments
with anti-HB-EGF reagents. However, direct regulation of
p21CIP1=WAF1 by proHB-EGF was not observed in this case
(Horikawa et al., unpublished observation). ProHB-EGF
might regulate other molecules involved in the cell cycle or
redox regulations.
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